Introduction. Ovarian cancer, being one of the most common gynecologic
cancers, has the highest mortality rate. The gold standard for the treatment
of patients with advanced ovarian cancer, along with angiogenesis inhibitors
applied in certain advanced stages, is cytoreductive surgery, followed by
chemotherapy (CHT). The use of chemotherapeutic agents in hemodialysis (HD)
patients has some specificities and limitations, and no CHT guidelines exist
for treating those patients. Case report. We present a 45-year-old female
patient with end-stage renal disease undergoing HD treatment. Abdominal and
pelvic magnetic resonance imaging showed a multicystic mass with a total
diameter of 93 ? 115 ? 168 mm in the right ovary and two subcapsular lesions
in the VI segment of the liver with a diameter of 22 ? 14 mm and 9 mm (stage
IVb ovarian cancer). The serum level of the tumor marker cancer antigen 125
(CA-125) was 93 U/mL. A total hysterectomy with bilateral
salpingo-oophorectomy and infracolic omentectomy was performed.
Histopathological analysis of the surgical specimen confirmed high-grade
serous ovarian adenocarcinoma, FIGO stage IVb. After surgery, she was
treated with carboplatin and paclitaxel combination CHT, determining the
dose of carboplatin according to the Calvert formula and initiating HD
within 20 hrs of infusion. Two years after the diagnosis was made, the
presented patient is in good condition. Conclusion. HD patients can be
treated with a combination CHT regimen of carboplatin and paclitaxel,
determining the dose of carboplatin according to the Calvert formula and
initiating HD within 20 hrs from the end of the chemotherapeutic infusion.